Literature DB >> 19079074

Targeting AMPA and kainate receptors in neurological disease: therapies on the horizon?

Geoffrey T Swanson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19079074      PMCID： PMC2715329          DOI： 10.1038/npp.2008.158

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN： 0893-133X            Impact factor:   7.853


× No keyword cloud information.
  5 in total

Review 1.  Talampanel.

Authors:  John F Howes; Cynthia Bell
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

Review 2.  Glutamate-based therapeutic approaches: ampakines.

Authors:  Gary Lynch
Journal:  Curr Opin Pharmacol       Date:  2005-12-19       Impact factor: 5.547

3.  Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial.

Authors:  Elizabeth Berry-Kravis; Sue Ellen Krause; Sandra S Block; Steve Guter; Joanne Wuu; Sue Leurgans; Penelope Decle; Kristina Potanos; Edwin Cook; Jeff Salt; Dominick Maino; Dahlia Weinberg; Rebecca Lara; Tristan Jardini; Jennifer Cogswell; Steven A Johnson; Randi Hagerman
Journal:  J Child Adolesc Psychopharmacol       Date:  2006-10       Impact factor: 2.576

4.  AMPA potentiator treatment of cognitive deficits in Alzheimer disease.

Authors:  A S Chappell; C Gonzales; J Williams; M M Witte; R C Mohs; R Sperling
Journal:  Neurology       Date:  2007-03-27       Impact factor: 9.910

Review 5.  AMPA receptor potentiators as cognitive enhancers.

Authors:  Michael J O'Neill; Sophie Dix
Journal:  IDrugs       Date:  2007-03
  5 in total
  19 in total

Review 1.  Interacting partners of AMPA-type glutamate receptors.

Authors:  Juan Cheng; Jie Dong; Yaxuan Cui; Liecheng Wang; Bei Wu; Chen Zhang
Journal:  J Mol Neurosci       Date:  2012-02-24       Impact factor: 3.444

Review 2.  Glutamate receptor ion channels: structure, regulation, and function.

Authors:  Stephen F Traynelis; Lonnie P Wollmuth; Chris J McBain; Frank S Menniti; Katie M Vance; Kevin K Ogden; Kasper B Hansen; Hongjie Yuan; Scott J Myers; Ray Dingledine
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

3.  Channel-opening kinetic mechanism for human wild-type GluK2 and the M867I mutant kainate receptor.

Authors:  Yan Han; Congzhou Wang; Jae Seon Park; Li Niu
Journal:  Biochemistry       Date:  2010-11-02       Impact factor: 3.162

4.  Functional analysis of a novel positive allosteric modulator of AMPA receptors derived from a structure-based drug design strategy.

Authors:  Jonathan E Harms; Morris Benveniste; John K F Maclean; Kathryn M Partin; Craig Jamieson
Journal:  Neuropharmacology       Date:  2012-06-23       Impact factor: 5.250

5.  Regulation of AMPA receptor subunit GluA1 surface expression by PAK3 phosphorylation.

Authors:  Natasha K Hussain; Gareth M Thomas; Junjie Luo; Richard L Huganir
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-12       Impact factor: 11.205

6.  5-Arylbenzothiadiazine Type Compounds as Positive Allosteric Modulators of AMPA/Kainate Receptors.

Authors:  Umberto M Battisti; Krzysztof Jozwiak; Giuseppe Cannazza; Giulia Puia; Gabriella Stocca; Daniela Braghiroli; Carlo Parenti; Livio Brasili; Marina M Carrozzo; Cinzia Citti; Luigino Troisi
Journal:  ACS Med Chem Lett       Date:  2011-11-14       Impact factor: 4.345

7.  Computational characterization of the glutamate receptor antagonist perampanel and its close analogs: density functional exploration of conformational space and molecular docking study.

Authors:  Abdul-Akim D Guseynov; Sergey A Pisarev; Dmitry A Shulga; Vladimir A Palyulin; Maxim V Fedorov; Dmitry S Karlov
Journal:  J Mol Model       Date:  2019-09-11       Impact factor: 1.810

8.  Identification and characterization of RNA aptamers: A long aptamer blocks the AMPA receptor and a short aptamer blocks both AMPA and kainate receptors.

Authors:  William J Jaremko; Zhen Huang; Wei Wen; Andrew Wu; Nicholas Karl; Li Niu
Journal:  J Biol Chem       Date:  2017-03-21       Impact factor: 5.157

9.  Pharmacological activity of C10-substituted analogs of the high-affinity kainate receptor agonist dysiherbaine.

Authors:  L Leanne Lash-Van Wyhe; Pekka A Postila; Koichi Tsubone; Makoto Sasaki; Olli T Pentikäinen; Ryuichi Sakai; Geoffrey T Swanson
Journal:  Neuropharmacology       Date:  2009-12-04       Impact factor: 5.250

10.  Probing the allosteric modulator binding site of GluR2 with thiazide derivatives.

Authors:  Christopher P Ptak; Ahmed H Ahmed; Robert E Oswald
Journal:  Biochemistry       Date:  2009-09-15       Impact factor: 3.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.